阿柏西普 (Eylea, Zaltrap, Yesafili +9)

概览

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer

作用机制

Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.

适应症

The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.

• Branch Retinal Vein Occlusion With Macular Edema
• Diabetic Macular Edema (DME)
• Diabetic Retinopathy (DR)
• Macular Edema
• Macular Edema With Central Retinal Vein Occlusions
• Metastatic Colorectal Cancer (CRC)
• Myopic Choroidal Neovascularization
• Neovascular Age-Related Macular Degeneration (nAMD)
• Retinopathy of Prematurity (ROP)